Greenwich LifeSciences Inc
For the period ended Dec 31, 2023. Filed Apr 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 15, 2024
GLSI$16.52+8.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ Equity
| Common Stock · Additional · Total | |||||
|---|---|---|---|---|---|
| Shares | Par Amount | Paid-in Capital | Accumulated Deficit | Stockholders’ Equity | |
| Balances, December 31, 2021 | 13,147,829 | $13,148 | $60,466,093 | $(33,647,529) | $26,831,712 |
| Stock-based compensation | 220,164 | 220 | 1,743,645 | — | 1,743,865 |
| Repurchase of common stock via stock repurchase program, net of costs | (519,828) | (520) | (7,535,696) | — | (7,536,216) |
| Net loss | (7,825,237) | (7,825,237) | |||
| Balances, December 31, 2022 | 12,848,165 | $12,848 | $54,674,042 | $(41,472,766) | $13,214,124 |
| Stock-based compensation | — | — | 2,378,088 | — | 2,378,088 |
| Net loss | (8,891,803) | (8,891,803) | |||
| Balances, December 31, 2023 | 12,848,165 | $12,848 | $57,052,130 | $(50,364,569) | $6,700,409 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.